Alligator Bioscience (LSE:0RK9) - Stock Price, News & Analysis

0RK9 Stock Overview

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.

About the company

0RK9 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 9.2% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Shares are highly illiquid

Does not have a meaningful market cap (SEK772M)

+ 1 more risk

Alligator Bioscience AB (publ) Competitors

Avacta Group

AIM:AVCT

UK£158.1m

Destiny Pharma

AIM:DEST

UK£21.0m

Tissue Regenix Group

AIM:TRX

UK£43.3m

Arecor Therapeutics

AIM:AREC

UK£40.6m

Price History & Performance

Summary of all time highs, changes and price drops for Alligator Bioscience
Historical stock prices
Current Share Price	kr1.12
52 Week High	kr1.51
52 Week Low	kr0.38
Beta	1.34
1 Month Change	0%
3 Month Change	8.11%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-95.63%
Change since IPO	-96.70%

Recent updates

Shareholder Returns

	0RK9	GB Biotechs	GB Market
7D	0%	0.5%	2.7%
1Y	n/a	-29.8%	0.3%

Return vs Industry: Insufficient data to determine how 0RK9 performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0RK9 performed against the UK Market.

Price Volatility

Is 0RK9's price volatile compared to industry and market?
0RK9 volatility
0RK9 Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.1%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0RK9 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0RK9's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	58	Søren Bregenholt	www.alligatorbioscience.se

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG

Alligator Bioscience AB (publ) Fundamentals Summary

How do Alligator Bioscience's earnings and revenue compare to its market cap?
0RK9 fundamental statistics
Market cap	kr771.68m
Earnings (TTM)	-kr248.59m
Revenue (TTM)	kr59.25m

13.0x

P/S Ratio

-3.1x

P/E Ratio

Is 0RK9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RK9 income statement (TTM)
Revenue	kr59.25m
Cost of Revenue	kr218.79m
Gross Profit	-kr159.54m
Other Expenses	kr89.05m
Earnings	-kr248.59m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 06, 2024

Earnings per share (EPS)	-0.33
Gross Margin	-269.26%
Net Profit Margin	-419.55%
Debt/Equity Ratio	0%

How did 0RK9 perform over the long term?

See historical performance and comparison

0RK9 Stock Overview

Rewards

Risk Analysis

Alligator Bioscience AB (publ) Competitors

AIM:AVCT

UK£158.1m

AIM:DEST

UK£21.0m

AIM:TRX

UK£43.3m

AIM:AREC

UK£40.6m

Price History & Performance

Recent News & Updates

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

High number of new and inexperienced directors

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

High number of new directors

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

High number of new directors

First quarter 2023 earnings released: kr0.28 loss per share (vs kr0.20 loss in 1Q 2022)

High number of new directors

High number of new directors

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

High number of new directors

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

High number of new directors

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

Alligator Bioscience AB (publ) Fundamentals Summary

13.0x

-3.1x

Earnings & Revenue